No Data
US Stock MarketDetailed Quotes
INAB In8bio
Watchlist
0.815
-0.018-2.14% Trading 11/30 13:22 ET
0.866High0.800Low66.65KVolume
0.866Open0.833Pre Close54.83KTurnover0.39%Turnover RatioLossP/E (TTM)26.07MMarket Cap3.95052wk HighLossP/E (Static)31.99MShares0.65052wk Low1.47P/B13.83MFloat Cap10.319Historical High--Dividend TTM16.96MShs Float0.650Historical Low--Div YieldTTM7.91%Amplitude0.822Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About In8bio Company
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
News
IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients With Newly Diagnosed Glioblastoma
IN8bio, Inc. (NASDAQ:INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies, presented data demonstrating that all patients treated with INB-
12 Health Care Stocks Moving In Friday's After-Market Session
GainersForte Biosciences (NASDAQ:FBRX) shares increased by 11.8% to $0.5 during Friday's after-market session. Today's trading volume for this security ended up closing at 287.3K shares, which is 905.
Promising Future for IN8bio: Anticipated Data Presentations, Capital Raise, and Innovative Developments
Comments
Update
$In8bio(INAB.US$ IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients With Newly Diagnosed Glioblastoma
Benzinga· 2 mins ago
Benzinga· 2 mins ago
1
Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--